Détails du produit
Synonyms
GDF15, GDF-15, MIC-1, MIC1, NAG-1, PDF, PLAB, PTGFB, NRG-1
Source
Cynomolgus GDF-15, His Tag (GD5-C5148) is expressed from E. coli cells. It contains AA Ala 197 - Val 308 (Accession # G7PWZ3-1).
Predicted N-terminus: Met
Request for sequenceMolecular Characterization

Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 14.4 kDa. The protein migrates as 16 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE).
Endotoxin
Less than 0.01 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in 20 mM Citric acid, pH2.2 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
SDS-PAGE

Cynomolgus GDF-15, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
Bioactivity-ELISA

Immobilized Cynomolgus GDF-15, His Tag (Cat. No. GD5-C5148) at 1 μg/mL (100 μL/well) can bind Human GFR alpha-like, Fc Tag (Cat. No. GFE-H5259) with a linear range of 0.8-25 ng/mL (QC tested).
Protocol
Avis des utilisateurs Publier un commentaire

Introduction de fond
Progrès de frontière
- Nom anglais:
Growth/differentiation factor 15
- Catégorie:
- Nombre de médicaments répertoriés:
0 Détails
- Nombre de médicaments cliniques:
10 Détails
- Étape de développement la plus élevée:
Phase 3 Clinical



















